nodes	percent_of_prediction	percent_of_DWPC	metapath
Lurasidone—CYP3A4—Rosuvastatin—atherosclerosis	0.0474	0.211	CbGbCtD
Lurasidone—CYP3A4—Ezetimibe—atherosclerosis	0.0474	0.211	CbGbCtD
Lurasidone—CYP3A4—Simvastatin—atherosclerosis	0.044	0.196	CbGbCtD
Lurasidone—CYP3A4—Lovastatin—atherosclerosis	0.0431	0.192	CbGbCtD
Lurasidone—CYP3A4—Pravastatin—atherosclerosis	0.0431	0.192	CbGbCtD
Lurasidone—HTR2A—arteriole—atherosclerosis	0.0162	0.163	CbGeAlD
Lurasidone—HTR7—vein—atherosclerosis	0.0155	0.156	CbGeAlD
Lurasidone—HTR2A—vein—atherosclerosis	0.00968	0.0972	CbGeAlD
Lurasidone—Ziprasidone—HRH1—atherosclerosis	0.0075	1	CrCbGaD
Lurasidone—HTR2A—hindlimb—atherosclerosis	0.00643	0.0646	CbGeAlD
Lurasidone—HTR7—artery—atherosclerosis	0.00632	0.0635	CbGeAlD
Lurasidone—Blood creatine phosphokinase increased—Rosuvastatin—atherosclerosis	0.00608	0.0133	CcSEcCtD
Lurasidone—Blood glucose increased—Niacin—atherosclerosis	0.00595	0.013	CcSEcCtD
Lurasidone—Pregnancy—Simvastatin—atherosclerosis	0.00584	0.0128	CcSEcCtD
Lurasidone—Creatine phosphokinase increased—Pravastatin—atherosclerosis	0.0057	0.0125	CcSEcCtD
Lurasidone—HTR2A—appendage—atherosclerosis	0.00552	0.0554	CbGeAlD
Lurasidone—Upset stomach—Lovastatin—atherosclerosis	0.00541	0.0119	CcSEcCtD
Lurasidone—HTR7—endothelium—atherosclerosis	0.00534	0.0536	CbGeAlD
Lurasidone—Blood creatine phosphokinase increased—Lovastatin—atherosclerosis	0.00515	0.0113	CcSEcCtD
Lurasidone—Upset stomach—Simvastatin—atherosclerosis	0.00506	0.0111	CcSEcCtD
Lurasidone—Blood creatine phosphokinase increased—Ezetimibe—atherosclerosis	0.00505	0.0111	CcSEcCtD
Lurasidone—HTR7—blood vessel—atherosclerosis	0.00492	0.0495	CbGeAlD
Lurasidone—Blood creatine phosphokinase increased—Simvastatin—atherosclerosis	0.00482	0.0106	CcSEcCtD
Lurasidone—Rhabdomyolysis—Rosuvastatin—atherosclerosis	0.00473	0.0104	CcSEcCtD
Lurasidone—Hypokinesia—Niacin—atherosclerosis	0.00451	0.00989	CcSEcCtD
Lurasidone—Blood creatine phosphokinase increased—Pravastatin—atherosclerosis	0.00436	0.00955	CcSEcCtD
Lurasidone—Nightmare—Rosuvastatin—atherosclerosis	0.00404	0.00886	CcSEcCtD
Lurasidone—Rhabdomyolysis—Lovastatin—atherosclerosis	0.00401	0.00878	CcSEcCtD
Lurasidone—HTR2A—artery—atherosclerosis	0.00394	0.0396	CbGeAlD
Lurasidone—Rhabdomyolysis—Ezetimibe—atherosclerosis	0.00393	0.00862	CcSEcCtD
Lurasidone—Rhabdomyolysis—Simvastatin—atherosclerosis	0.00375	0.00822	CcSEcCtD
Lurasidone—Neck pain—Ezetimibe—atherosclerosis	0.00352	0.00772	CcSEcCtD
Lurasidone—Sleep disorder—Rosuvastatin—atherosclerosis	0.00351	0.00769	CcSEcCtD
Lurasidone—Diabetes mellitus—Rosuvastatin—atherosclerosis	0.00349	0.00765	CcSEcCtD
Lurasidone—Breast pain—Niacin—atherosclerosis	0.00349	0.00765	CcSEcCtD
Lurasidone—Rhabdomyolysis—Niacin—atherosclerosis	0.00344	0.00754	CcSEcCtD
Lurasidone—Rhabdomyolysis—Pravastatin—atherosclerosis	0.00339	0.00743	CcSEcCtD
Lurasidone—HTR2A—endothelium—atherosclerosis	0.00333	0.0335	CbGeAlD
Lurasidone—Nightmare—Simvastatin—atherosclerosis	0.0032	0.00702	CcSEcCtD
Lurasidone—HTR2A—blood vessel—atherosclerosis	0.00307	0.0308	CbGeAlD
Lurasidone—Nightmare—Pravastatin—atherosclerosis	0.00289	0.00635	CcSEcCtD
Lurasidone—Sleep disorder—Simvastatin—atherosclerosis	0.00278	0.0061	CcSEcCtD
Lurasidone—Diabetes mellitus—Simvastatin—atherosclerosis	0.00277	0.00607	CcSEcCtD
Lurasidone—Breast disorder—Rosuvastatin—atherosclerosis	0.00274	0.00602	CcSEcCtD
Lurasidone—Hot flush—Ezetimibe—atherosclerosis	0.0027	0.00592	CcSEcCtD
Lurasidone—Menopausal symptoms—Ezetimibe—atherosclerosis	0.00267	0.00587	CcSEcCtD
Lurasidone—Influenza—Rosuvastatin—atherosclerosis	0.00262	0.00575	CcSEcCtD
Lurasidone—Diabetes mellitus—Niacin—atherosclerosis	0.00254	0.00557	CcSEcCtD
Lurasidone—HTR7—connective tissue—atherosclerosis	0.00252	0.0254	CbGeAlD
Lurasidone—Sleep disorder—Pravastatin—atherosclerosis	0.00251	0.00551	CcSEcCtD
Lurasidone—Hot flush—Pravastatin—atherosclerosis	0.00233	0.0051	CcSEcCtD
Lurasidone—Menopausal symptoms—Pravastatin—atherosclerosis	0.00231	0.00506	CcSEcCtD
Lurasidone—HTR1A—cardiovascular system—atherosclerosis	0.0023	0.0231	CbGeAlD
Lurasidone—Breast disorder—Ezetimibe—atherosclerosis	0.00228	0.005	CcSEcCtD
Lurasidone—Urinary tract infection—Rosuvastatin—atherosclerosis	0.00227	0.00499	CcSEcCtD
Lurasidone—Nasopharyngitis—Ezetimibe—atherosclerosis	0.00226	0.00495	CcSEcCtD
Lurasidone—Gastritis—Ezetimibe—atherosclerosis	0.00223	0.0049	CcSEcCtD
Lurasidone—Alanine aminotransferase increased—Ezetimibe—atherosclerosis	0.00223	0.00488	CcSEcCtD
Lurasidone—Influenza—Lovastatin—atherosclerosis	0.00222	0.00488	CcSEcCtD
Lurasidone—Hepatobiliary disease—Rosuvastatin—atherosclerosis	0.00221	0.00485	CcSEcCtD
Lurasidone—Eosinophilia—Lovastatin—atherosclerosis	0.0022	0.00483	CcSEcCtD
Lurasidone—HTR7—cardiovascular system—atherosclerosis	0.0022	0.0221	CbGeAlD
Lurasidone—Influenza—Ezetimibe—atherosclerosis	0.00218	0.00478	CcSEcCtD
Lurasidone—Eosinophilia—Ezetimibe—atherosclerosis	0.00216	0.00474	CcSEcCtD
Lurasidone—Abdominal discomfort—Lovastatin—atherosclerosis	0.00213	0.00468	CcSEcCtD
Lurasidone—Gastritis—Simvastatin—atherosclerosis	0.00213	0.00467	CcSEcCtD
Lurasidone—Eosinophilia—Simvastatin—atherosclerosis	0.00206	0.00452	CcSEcCtD
Lurasidone—Erectile dysfunction—Lovastatin—atherosclerosis	0.00205	0.00449	CcSEcCtD
Lurasidone—Orthostatic hypotension—Niacin—atherosclerosis	0.00202	0.00443	CcSEcCtD
Lurasidone—Erectile dysfunction—Ezetimibe—atherosclerosis	0.00201	0.00441	CcSEcCtD
Lurasidone—Abdominal discomfort—Simvastatin—atherosclerosis	0.00199	0.00437	CcSEcCtD
Lurasidone—Nasopharyngitis—Pravastatin—atherosclerosis	0.00195	0.00427	CcSEcCtD
Lurasidone—Infestation NOS—Ezetimibe—atherosclerosis	0.00195	0.00426	CcSEcCtD
Lurasidone—Infestation—Ezetimibe—atherosclerosis	0.00195	0.00426	CcSEcCtD
Lurasidone—Urinary tract infection—Lovastatin—atherosclerosis	0.00193	0.00423	CcSEcCtD
Lurasidone—Alanine aminotransferase increased—Pravastatin—atherosclerosis	0.00192	0.00421	CcSEcCtD
Lurasidone—Erectile dysfunction—Simvastatin—atherosclerosis	0.00192	0.0042	CcSEcCtD
Lurasidone—Influenza—Niacin—atherosclerosis	0.00191	0.00419	CcSEcCtD
Lurasidone—Dysphagia—Niacin—atherosclerosis	0.00191	0.00419	CcSEcCtD
Lurasidone—Influenza—Pravastatin—atherosclerosis	0.00188	0.00412	CcSEcCtD
Lurasidone—Arrhythmia—Rosuvastatin—atherosclerosis	0.00188	0.00411	CcSEcCtD
Lurasidone—Eosinophilia—Pravastatin—atherosclerosis	0.00186	0.00408	CcSEcCtD
Lurasidone—Angina pectoris—Niacin—atherosclerosis	0.00186	0.00408	CcSEcCtD
Lurasidone—ADRA2A—connective tissue—atherosclerosis	0.00185	0.0186	CbGeAlD
Lurasidone—Mental disorder—Rosuvastatin—atherosclerosis	0.00184	0.00404	CcSEcCtD
Lurasidone—Hepatobiliary disease—Ezetimibe—atherosclerosis	0.00184	0.00403	CcSEcCtD
Lurasidone—Angina pectoris—Pravastatin—atherosclerosis	0.00183	0.00402	CcSEcCtD
Lurasidone—Flatulence—Rosuvastatin—atherosclerosis	0.0018	0.00395	CcSEcCtD
Lurasidone—ADRA2C—adipose tissue—atherosclerosis	0.00178	0.0179	CbGeAlD
Lurasidone—Erectile dysfunction—Niacin—atherosclerosis	0.00176	0.00386	CcSEcCtD
Lurasidone—Dysuria—Pravastatin—atherosclerosis	0.00176	0.00386	CcSEcCtD
Lurasidone—Erectile dysfunction—Pravastatin—atherosclerosis	0.00173	0.0038	CcSEcCtD
Lurasidone—Connective tissue disorder—Ezetimibe—atherosclerosis	0.00172	0.00376	CcSEcCtD
Lurasidone—Weight increased—Pravastatin—atherosclerosis	0.00171	0.00375	CcSEcCtD
Lurasidone—Angioedema—Rosuvastatin—atherosclerosis	0.00167	0.00366	CcSEcCtD
Lurasidone—Urinary tract infection—Pravastatin—atherosclerosis	0.00163	0.00357	CcSEcCtD
Lurasidone—Angiopathy—Ezetimibe—atherosclerosis	0.00158	0.00347	CcSEcCtD
Lurasidone—HTR2A—connective tissue—atherosclerosis	0.00157	0.0158	CbGeAlD
Lurasidone—Myalgia—Rosuvastatin—atherosclerosis	0.00156	0.00341	CcSEcCtD
Lurasidone—Mental disorder—Ezetimibe—atherosclerosis	0.00153	0.00335	CcSEcCtD
Lurasidone—Flatulence—Lovastatin—atherosclerosis	0.00153	0.00335	CcSEcCtD
Lurasidone—Malnutrition—Ezetimibe—atherosclerosis	0.00152	0.00333	CcSEcCtD
Lurasidone—Back pain—Lovastatin—atherosclerosis	0.0015	0.00329	CcSEcCtD
Lurasidone—Flatulence—Ezetimibe—atherosclerosis	0.0015	0.00328	CcSEcCtD
Lurasidone—Muscle spasms—Lovastatin—atherosclerosis	0.00149	0.00327	CcSEcCtD
Lurasidone—Infection—Rosuvastatin—atherosclerosis	0.00148	0.00325	CcSEcCtD
Lurasidone—Back pain—Ezetimibe—atherosclerosis	0.00147	0.00322	CcSEcCtD
Lurasidone—Nervous system disorder—Rosuvastatin—atherosclerosis	0.00146	0.00321	CcSEcCtD
Lurasidone—Muscle spasms—Ezetimibe—atherosclerosis	0.00146	0.0032	CcSEcCtD
Lurasidone—Vision blurred—Lovastatin—atherosclerosis	0.00146	0.0032	CcSEcCtD
Lurasidone—Mental disorder—Simvastatin—atherosclerosis	0.00146	0.0032	CcSEcCtD
Lurasidone—Tremor—Lovastatin—atherosclerosis	0.00145	0.00318	CcSEcCtD
Lurasidone—Eye disorder—Niacin—atherosclerosis	0.00143	0.00313	CcSEcCtD
Lurasidone—Flatulence—Simvastatin—atherosclerosis	0.00143	0.00313	CcSEcCtD
Lurasidone—ADRA2A—adipose tissue—atherosclerosis	0.00142	0.0143	CbGeAlD
Lurasidone—Angioedema—Lovastatin—atherosclerosis	0.00142	0.0031	CcSEcCtD
Lurasidone—Anaemia—Ezetimibe—atherosclerosis	0.0014	0.00308	CcSEcCtD
Lurasidone—Malaise—Lovastatin—atherosclerosis	0.0014	0.00306	CcSEcCtD
Lurasidone—Cardiac disorder—Pravastatin—atherosclerosis	0.0014	0.00306	CcSEcCtD
Lurasidone—Muscle spasms—Simvastatin—atherosclerosis	0.00139	0.00306	CcSEcCtD
Lurasidone—Vertigo—Lovastatin—atherosclerosis	0.00139	0.00305	CcSEcCtD
Lurasidone—Angioedema—Ezetimibe—atherosclerosis	0.00139	0.00305	CcSEcCtD
Lurasidone—Angiopathy—Niacin—atherosclerosis	0.00139	0.00304	CcSEcCtD
Lurasidone—Leukopenia—Lovastatin—atherosclerosis	0.00139	0.00304	CcSEcCtD
Lurasidone—Malaise—Ezetimibe—atherosclerosis	0.00137	0.00301	CcSEcCtD
Lurasidone—HTR2A—cardiovascular system—atherosclerosis	0.00137	0.0138	CbGeAlD
Lurasidone—Vision blurred—Simvastatin—atherosclerosis	0.00137	0.003	CcSEcCtD
Lurasidone—Arrhythmia—Niacin—atherosclerosis	0.00137	0.00299	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.00136	0.00298	CcSEcCtD
Lurasidone—HTR7—liver—atherosclerosis	0.00136	0.0136	CbGeAlD
Lurasidone—Tremor—Simvastatin—atherosclerosis	0.00136	0.00298	CcSEcCtD
Lurasidone—Insomnia—Rosuvastatin—atherosclerosis	0.00135	0.00296	CcSEcCtD
Lurasidone—Arrhythmia—Pravastatin—atherosclerosis	0.00134	0.00295	CcSEcCtD
Lurasidone—Anaemia—Simvastatin—atherosclerosis	0.00134	0.00294	CcSEcCtD
Lurasidone—Malnutrition—Niacin—atherosclerosis	0.00133	0.00292	CcSEcCtD
Lurasidone—Angioedema—Simvastatin—atherosclerosis	0.00132	0.0029	CcSEcCtD
Lurasidone—Myalgia—Lovastatin—atherosclerosis	0.00132	0.00289	CcSEcCtD
Lurasidone—Anxiety—Lovastatin—atherosclerosis	0.00131	0.00288	CcSEcCtD
Lurasidone—Dyspepsia—Rosuvastatin—atherosclerosis	0.00131	0.00288	CcSEcCtD
Lurasidone—Hypertension—Ezetimibe—atherosclerosis	0.00131	0.00288	CcSEcCtD
Lurasidone—Flatulence—Niacin—atherosclerosis	0.00131	0.00288	CcSEcCtD
Lurasidone—Malaise—Simvastatin—atherosclerosis	0.00131	0.00287	CcSEcCtD
Lurasidone—Vertigo—Simvastatin—atherosclerosis	0.0013	0.00286	CcSEcCtD
Lurasidone—Leukopenia—Simvastatin—atherosclerosis	0.0013	0.00284	CcSEcCtD
Lurasidone—Myalgia—Ezetimibe—atherosclerosis	0.00129	0.00284	CcSEcCtD
Lurasidone—Flatulence—Pravastatin—atherosclerosis	0.00129	0.00283	CcSEcCtD
Lurasidone—Dry mouth—Lovastatin—atherosclerosis	0.00129	0.00283	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.00129	0.00282	CcSEcCtD
Lurasidone—Muscle spasms—Niacin—atherosclerosis	0.00128	0.00281	CcSEcCtD
Lurasidone—Dry mouth—Ezetimibe—atherosclerosis	0.00127	0.00277	CcSEcCtD
Lurasidone—Muscle spasms—Pravastatin—atherosclerosis	0.00126	0.00276	CcSEcCtD
Lurasidone—Infection—Lovastatin—atherosclerosis	0.00126	0.00276	CcSEcCtD
Lurasidone—Vision blurred—Niacin—atherosclerosis	0.00125	0.00275	CcSEcCtD
Lurasidone—ADRA2C—liver—atherosclerosis	0.00125	0.0125	CbGeAlD
Lurasidone—Vision blurred—Pravastatin—atherosclerosis	0.00124	0.00271	CcSEcCtD
Lurasidone—Myalgia—Simvastatin—atherosclerosis	0.00123	0.00271	CcSEcCtD
Lurasidone—Infection—Ezetimibe—atherosclerosis	0.00123	0.0027	CcSEcCtD
Lurasidone—Anxiety—Simvastatin—atherosclerosis	0.00123	0.0027	CcSEcCtD
Lurasidone—Tremor—Pravastatin—atherosclerosis	0.00123	0.00269	CcSEcCtD
Lurasidone—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.00122	0.00268	CcSEcCtD
Lurasidone—Nervous system disorder—Ezetimibe—atherosclerosis	0.00122	0.00267	CcSEcCtD
Lurasidone—Angioedema—Niacin—atherosclerosis	0.00122	0.00267	CcSEcCtD
Lurasidone—Anaemia—Pravastatin—atherosclerosis	0.00121	0.00266	CcSEcCtD
Lurasidone—Skin disorder—Ezetimibe—atherosclerosis	0.0012	0.00264	CcSEcCtD
Lurasidone—Angioedema—Pravastatin—atherosclerosis	0.0012	0.00263	CcSEcCtD
Lurasidone—Vertigo—Niacin—atherosclerosis	0.0012	0.00262	CcSEcCtD
Lurasidone—Syncope—Niacin—atherosclerosis	0.00119	0.00262	CcSEcCtD
Lurasidone—Leukopenia—Niacin—atherosclerosis	0.00119	0.00261	CcSEcCtD
Lurasidone—Malaise—Pravastatin—atherosclerosis	0.00118	0.00259	CcSEcCtD
Lurasidone—Abdominal pain—Rosuvastatin—atherosclerosis	0.00118	0.00259	CcSEcCtD
Lurasidone—Vertigo—Pravastatin—atherosclerosis	0.00118	0.00258	CcSEcCtD
Lurasidone—Infection—Simvastatin—atherosclerosis	0.00118	0.00258	CcSEcCtD
Lurasidone—Leukopenia—Pravastatin—atherosclerosis	0.00117	0.00257	CcSEcCtD
Lurasidone—Loss of consciousness—Niacin—atherosclerosis	0.00117	0.00257	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.00115	0.00253	CcSEcCtD
Lurasidone—Insomnia—Lovastatin—atherosclerosis	0.00114	0.00251	CcSEcCtD
Lurasidone—Myalgia—Niacin—atherosclerosis	0.00113	0.00248	CcSEcCtD
Lurasidone—Hypertension—Pravastatin—atherosclerosis	0.00113	0.00248	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.00113	0.00248	CcSEcCtD
Lurasidone—Dyspnoea—Lovastatin—atherosclerosis	0.00113	0.00247	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.00113	0.00247	CcSEcCtD
Lurasidone—Insomnia—Ezetimibe—atherosclerosis	0.00112	0.00246	CcSEcCtD
Lurasidone—Myalgia—Pravastatin—atherosclerosis	0.00112	0.00245	CcSEcCtD
Lurasidone—Dyspepsia—Lovastatin—atherosclerosis	0.00111	0.00244	CcSEcCtD
Lurasidone—Anxiety—Pravastatin—atherosclerosis	0.00111	0.00244	CcSEcCtD
Lurasidone—Dry mouth—Niacin—atherosclerosis	0.00111	0.00243	CcSEcCtD
Lurasidone—Dyspnoea—Ezetimibe—atherosclerosis	0.00111	0.00243	CcSEcCtD
Lurasidone—Decreased appetite—Lovastatin—atherosclerosis	0.0011	0.00241	CcSEcCtD
Lurasidone—Dyspepsia—Ezetimibe—atherosclerosis	0.00109	0.00239	CcSEcCtD
Lurasidone—Fatigue—Lovastatin—atherosclerosis	0.00109	0.00239	CcSEcCtD
Lurasidone—Decreased appetite—Ezetimibe—atherosclerosis	0.00108	0.00236	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.00108	0.00236	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.00107	0.00235	CcSEcCtD
Lurasidone—Asthenia—Rosuvastatin—atherosclerosis	0.00107	0.00235	CcSEcCtD
Lurasidone—Insomnia—Simvastatin—atherosclerosis	0.00107	0.00235	CcSEcCtD
Lurasidone—Fatigue—Ezetimibe—atherosclerosis	0.00107	0.00235	CcSEcCtD
Lurasidone—Shock—Niacin—atherosclerosis	0.00107	0.00234	CcSEcCtD
Lurasidone—Infection—Pravastatin—atherosclerosis	0.00106	0.00233	CcSEcCtD
Lurasidone—Tachycardia—Niacin—atherosclerosis	0.00106	0.00232	CcSEcCtD
Lurasidone—Pruritus—Rosuvastatin—atherosclerosis	0.00106	0.00232	CcSEcCtD
Lurasidone—Skin disorder—Niacin—atherosclerosis	0.00106	0.00231	CcSEcCtD
Lurasidone—Dyspnoea—Simvastatin—atherosclerosis	0.00105	0.00231	CcSEcCtD
Lurasidone—Hyperhidrosis—Niacin—atherosclerosis	0.00105	0.0023	CcSEcCtD
Lurasidone—Dyspepsia—Simvastatin—atherosclerosis	0.00104	0.00228	CcSEcCtD
Lurasidone—Gastrointestinal pain—Lovastatin—atherosclerosis	0.00103	0.00227	CcSEcCtD
Lurasidone—Hyperhidrosis—Pravastatin—atherosclerosis	0.00103	0.00227	CcSEcCtD
Lurasidone—Decreased appetite—Simvastatin—atherosclerosis	0.00103	0.00225	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.00102	0.00224	CcSEcCtD
Lurasidone—Diarrhoea—Rosuvastatin—atherosclerosis	0.00102	0.00224	CcSEcCtD
Lurasidone—Fatigue—Simvastatin—atherosclerosis	0.00102	0.00224	CcSEcCtD
Lurasidone—Hypotension—Niacin—atherosclerosis	0.00102	0.00223	CcSEcCtD
Lurasidone—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.00101	0.00222	CcSEcCtD
Lurasidone—Abdominal pain—Lovastatin—atherosclerosis	0.001	0.00219	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Niacin—atherosclerosis	0.00099	0.00217	CcSEcCtD
Lurasidone—Dizziness—Rosuvastatin—atherosclerosis	0.000987	0.00216	CcSEcCtD
Lurasidone—Insomnia—Niacin—atherosclerosis	0.000982	0.00215	CcSEcCtD
Lurasidone—Abdominal pain—Ezetimibe—atherosclerosis	0.000981	0.00215	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000974	0.00214	CcSEcCtD
Lurasidone—Dyspnoea—Niacin—atherosclerosis	0.000968	0.00212	CcSEcCtD
Lurasidone—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000967	0.00212	CcSEcCtD
Lurasidone—Insomnia—Pravastatin—atherosclerosis	0.000967	0.00212	CcSEcCtD
Lurasidone—Somnolence—Niacin—atherosclerosis	0.000966	0.00212	CcSEcCtD
Lurasidone—Dyspepsia—Niacin—atherosclerosis	0.000956	0.0021	CcSEcCtD
Lurasidone—Dyspnoea—Pravastatin—atherosclerosis	0.000954	0.00209	CcSEcCtD
Lurasidone—Decreased appetite—Niacin—atherosclerosis	0.000944	0.00207	CcSEcCtD
Lurasidone—Dyspepsia—Pravastatin—atherosclerosis	0.000941	0.00206	CcSEcCtD
Lurasidone—Rash—Rosuvastatin—atherosclerosis	0.000941	0.00206	CcSEcCtD
Lurasidone—Dermatitis—Rosuvastatin—atherosclerosis	0.00094	0.00206	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Niacin—atherosclerosis	0.000938	0.00206	CcSEcCtD
Lurasidone—Abdominal pain—Simvastatin—atherosclerosis	0.000935	0.00205	CcSEcCtD
Lurasidone—Decreased appetite—Pravastatin—atherosclerosis	0.00093	0.00204	CcSEcCtD
Lurasidone—Fatigue—Pravastatin—atherosclerosis	0.000922	0.00202	CcSEcCtD
Lurasidone—Asthenia—Lovastatin—atherosclerosis	0.000907	0.00199	CcSEcCtD
Lurasidone—Pruritus—Lovastatin—atherosclerosis	0.000895	0.00196	CcSEcCtD
Lurasidone—Asthenia—Ezetimibe—atherosclerosis	0.00089	0.00195	CcSEcCtD
Lurasidone—Gastrointestinal pain—Niacin—atherosclerosis	0.000888	0.00195	CcSEcCtD
Lurasidone—Nausea—Rosuvastatin—atherosclerosis	0.000886	0.00194	CcSEcCtD
Lurasidone—Pruritus—Ezetimibe—atherosclerosis	0.000878	0.00192	CcSEcCtD
Lurasidone—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000875	0.00192	CcSEcCtD
Lurasidone—Diarrhoea—Lovastatin—atherosclerosis	0.000865	0.0019	CcSEcCtD
Lurasidone—Abdominal pain—Niacin—atherosclerosis	0.000859	0.00188	CcSEcCtD
Lurasidone—Asthenia—Simvastatin—atherosclerosis	0.000849	0.00186	CcSEcCtD
Lurasidone—Diarrhoea—Ezetimibe—atherosclerosis	0.000849	0.00186	CcSEcCtD
Lurasidone—HTR2A—liver—atherosclerosis	0.000847	0.00851	CbGeAlD
Lurasidone—Abdominal pain—Pravastatin—atherosclerosis	0.000845	0.00185	CcSEcCtD
Lurasidone—Pruritus—Simvastatin—atherosclerosis	0.000837	0.00184	CcSEcCtD
Lurasidone—Dizziness—Lovastatin—atherosclerosis	0.000836	0.00183	CcSEcCtD
Lurasidone—Dizziness—Ezetimibe—atherosclerosis	0.00082	0.0018	CcSEcCtD
Lurasidone—Diarrhoea—Simvastatin—atherosclerosis	0.000809	0.00177	CcSEcCtD
Lurasidone—Vomiting—Lovastatin—atherosclerosis	0.000804	0.00176	CcSEcCtD
Lurasidone—Rash—Lovastatin—atherosclerosis	0.000797	0.00175	CcSEcCtD
Lurasidone—Dermatitis—Lovastatin—atherosclerosis	0.000797	0.00175	CcSEcCtD
Lurasidone—Vomiting—Ezetimibe—atherosclerosis	0.000789	0.00173	CcSEcCtD
Lurasidone—CYP3A4—liver—atherosclerosis	0.000784	0.00788	CbGeAlD
Lurasidone—Dizziness—Simvastatin—atherosclerosis	0.000782	0.00172	CcSEcCtD
Lurasidone—Rash—Ezetimibe—atherosclerosis	0.000782	0.00172	CcSEcCtD
Lurasidone—Dermatitis—Ezetimibe—atherosclerosis	0.000781	0.00171	CcSEcCtD
Lurasidone—Asthenia—Niacin—atherosclerosis	0.000779	0.00171	CcSEcCtD
Lurasidone—Pruritus—Niacin—atherosclerosis	0.000769	0.00169	CcSEcCtD
Lurasidone—Asthenia—Pravastatin—atherosclerosis	0.000767	0.00168	CcSEcCtD
Lurasidone—Pruritus—Pravastatin—atherosclerosis	0.000757	0.00166	CcSEcCtD
Lurasidone—Vomiting—Simvastatin—atherosclerosis	0.000752	0.00165	CcSEcCtD
Lurasidone—Nausea—Lovastatin—atherosclerosis	0.000751	0.00165	CcSEcCtD
Lurasidone—Rash—Simvastatin—atherosclerosis	0.000746	0.00164	CcSEcCtD
Lurasidone—Dermatitis—Simvastatin—atherosclerosis	0.000745	0.00163	CcSEcCtD
Lurasidone—Diarrhoea—Niacin—atherosclerosis	0.000743	0.00163	CcSEcCtD
Lurasidone—Nausea—Ezetimibe—atherosclerosis	0.000737	0.00162	CcSEcCtD
Lurasidone—Diarrhoea—Pravastatin—atherosclerosis	0.000732	0.0016	CcSEcCtD
Lurasidone—Dizziness—Niacin—atherosclerosis	0.000718	0.00158	CcSEcCtD
Lurasidone—Dizziness—Pravastatin—atherosclerosis	0.000707	0.00155	CcSEcCtD
Lurasidone—Nausea—Simvastatin—atherosclerosis	0.000703	0.00154	CcSEcCtD
Lurasidone—Vomiting—Niacin—atherosclerosis	0.000691	0.00151	CcSEcCtD
Lurasidone—Rash—Niacin—atherosclerosis	0.000685	0.0015	CcSEcCtD
Lurasidone—Dermatitis—Niacin—atherosclerosis	0.000684	0.0015	CcSEcCtD
Lurasidone—Vomiting—Pravastatin—atherosclerosis	0.00068	0.00149	CcSEcCtD
Lurasidone—Rash—Pravastatin—atherosclerosis	0.000674	0.00148	CcSEcCtD
Lurasidone—Dermatitis—Pravastatin—atherosclerosis	0.000674	0.00148	CcSEcCtD
Lurasidone—Nausea—Niacin—atherosclerosis	0.000645	0.00141	CcSEcCtD
Lurasidone—Nausea—Pravastatin—atherosclerosis	0.000635	0.00139	CcSEcCtD
Lurasidone—HTR2A—Signaling Pathways—MMP3—atherosclerosis	3.38e-05	0.000159	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—IGF1—atherosclerosis	3.37e-05	0.000159	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IGF2—atherosclerosis	3.36e-05	0.000159	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PLG—atherosclerosis	3.36e-05	0.000158	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—APOB—atherosclerosis	3.32e-05	0.000157	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—GPX1—atherosclerosis	3.31e-05	0.000156	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—SPP1—atherosclerosis	3.31e-05	0.000156	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CYP27A1—atherosclerosis	3.29e-05	0.000155	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—CXCL8—atherosclerosis	3.29e-05	0.000155	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—CXCL8—atherosclerosis	3.29e-05	0.000155	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—EDN1—atherosclerosis	3.26e-05	0.000154	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—APOB—atherosclerosis	3.26e-05	0.000154	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CCL5—atherosclerosis	3.24e-05	0.000153	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—CXCL8—atherosclerosis	3.24e-05	0.000153	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—CD36—atherosclerosis	3.22e-05	0.000152	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—EDN1—atherosclerosis	3.21e-05	0.000152	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—SERPINE1—atherosclerosis	3.2e-05	0.000151	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CCL5—atherosclerosis	3.19e-05	0.00015	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—SOCS3—atherosclerosis	3.18e-05	0.00015	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—LPL—atherosclerosis	3.17e-05	0.000149	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PDGFB—atherosclerosis	3.16e-05	0.000149	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PIK3CG—atherosclerosis	3.16e-05	0.000149	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—APOA2—atherosclerosis	3.12e-05	0.000147	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	3.12e-05	0.000147	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	3.12e-05	0.000147	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ALOX15—atherosclerosis	3.12e-05	0.000147	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—LPL—atherosclerosis	3.12e-05	0.000147	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—AGT—atherosclerosis	3.09e-05	0.000146	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ABCG5—atherosclerosis	3.08e-05	0.000146	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PRKCG—atherosclerosis	3.08e-05	0.000145	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MMP3—atherosclerosis	3.07e-05	0.000145	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PDGFB—atherosclerosis	3.06e-05	0.000144	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IGF2—atherosclerosis	3.06e-05	0.000144	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—NOS3—atherosclerosis	3.06e-05	0.000144	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—MTHFR—atherosclerosis	3.05e-05	0.000144	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PPARG—atherosclerosis	3.05e-05	0.000144	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PRKCG—atherosclerosis	3.03e-05	0.000143	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—LEP—atherosclerosis	3.02e-05	0.000143	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—APOE—atherosclerosis	3.02e-05	0.000143	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—SPP1—atherosclerosis	3e-05	0.000142	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CAV1—atherosclerosis	3e-05	0.000141	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PPARA—atherosclerosis	2.99e-05	0.000141	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—INS—atherosclerosis	2.99e-05	0.000141	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—APOA1—atherosclerosis	2.99e-05	0.000141	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—CXCL8—atherosclerosis	2.99e-05	0.000141	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—AGT—atherosclerosis	2.99e-05	0.000141	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—LPA—atherosclerosis	2.98e-05	0.000141	CbGpPWpGaD
Lurasidone—ADRA2C—Hemostasis—AKT1—atherosclerosis	2.97e-05	0.00014	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—APOB—atherosclerosis	2.97e-05	0.00014	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—SPP1—atherosclerosis	2.95e-05	0.000139	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—CXCL8—atherosclerosis	2.94e-05	0.000139	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—CXCL8—atherosclerosis	2.94e-05	0.000139	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—APOE—atherosclerosis	2.93e-05	0.000138	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—LEP—atherosclerosis	2.93e-05	0.000138	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—EDN1—atherosclerosis	2.92e-05	0.000138	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—AGT—atherosclerosis	2.9e-05	0.000137	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CCL5—atherosclerosis	2.9e-05	0.000137	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CAV1—atherosclerosis	2.9e-05	0.000137	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—APOA1—atherosclerosis	2.89e-05	0.000136	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—ESR1—atherosclerosis	2.89e-05	0.000136	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—BGN—atherosclerosis	2.89e-05	0.000136	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—APOA5—atherosclerosis	2.86e-05	0.000135	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—F2—atherosclerosis	2.85e-05	0.000135	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—APOE—atherosclerosis	2.84e-05	0.000134	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—LPL—atherosclerosis	2.83e-05	0.000134	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—CAV1—atherosclerosis	2.82e-05	0.000133	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—APOA1—atherosclerosis	2.81e-05	0.000133	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—ESR1—atherosclerosis	2.79e-05	0.000132	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PDGFB—atherosclerosis	2.77e-05	0.000131	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—F2—atherosclerosis	2.76e-05	0.00013	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PRKCG—atherosclerosis	2.76e-05	0.00013	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	2.75e-05	0.00013	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—ALB—atherosclerosis	2.74e-05	0.000129	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PDGFB—atherosclerosis	2.73e-05	0.000129	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PIK3CG—atherosclerosis	2.73e-05	0.000129	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—CXCL8—atherosclerosis	2.71e-05	0.000128	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—AGT—atherosclerosis	2.71e-05	0.000128	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—SPP1—atherosclerosis	2.68e-05	0.000127	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—CXCL8—atherosclerosis	2.67e-05	0.000126	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—AGT—atherosclerosis	2.67e-05	0.000126	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ALOX5—atherosclerosis	2.66e-05	0.000125	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—LEP—atherosclerosis	2.65e-05	0.000125	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—APOE—atherosclerosis	2.65e-05	0.000125	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PIK3CG—atherosclerosis	2.64e-05	0.000125	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CAV1—atherosclerosis	2.63e-05	0.000124	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—APOA1—atherosclerosis	2.62e-05	0.000124	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—NOS3—atherosclerosis	2.62e-05	0.000124	CbGpPWpGaD
Lurasidone—HTR7—GPCR downstream signaling—AKT1—atherosclerosis	2.62e-05	0.000124	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—MAPK3—atherosclerosis	2.61e-05	0.000123	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—LEP—atherosclerosis	2.61e-05	0.000123	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—APOE—atherosclerosis	2.61e-05	0.000123	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CAV1—atherosclerosis	2.59e-05	0.000122	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—INS—atherosclerosis	2.58e-05	0.000122	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—APOA1—atherosclerosis	2.58e-05	0.000122	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—IL6—atherosclerosis	2.58e-05	0.000122	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PIK3CG—atherosclerosis	2.56e-05	0.000121	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CCL2—atherosclerosis	2.54e-05	0.00012	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—ESR1—atherosclerosis	2.53e-05	0.00012	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—MAPK3—atherosclerosis	2.53e-05	0.000119	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—F2—atherosclerosis	2.5e-05	0.000118	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—INS—atherosclerosis	2.5e-05	0.000118	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—IGF1—atherosclerosis	2.5e-05	0.000118	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—ESR1—atherosclerosis	2.49e-05	0.000118	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PDGFB—atherosclerosis	2.48e-05	0.000117	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PPARG—atherosclerosis	2.48e-05	0.000117	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—F2—atherosclerosis	2.46e-05	0.000116	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CCL2—atherosclerosis	2.46e-05	0.000116	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—MMP9—atherosclerosis	2.45e-05	0.000116	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—INS—atherosclerosis	2.43e-05	0.000115	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—NFKB1—atherosclerosis	2.43e-05	0.000114	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—AGT—atherosclerosis	2.42e-05	0.000114	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—IGF1—atherosclerosis	2.42e-05	0.000114	CbGpPWpGaD
Lurasidone—ADRA2A—Hemostasis—AKT1—atherosclerosis	2.41e-05	0.000114	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PTGS2—atherosclerosis	2.4e-05	0.000113	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PIK3CG—atherosclerosis	2.4e-05	0.000113	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—MAPK8—atherosclerosis	2.38e-05	0.000113	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—NAMPT—atherosclerosis	2.38e-05	0.000112	CbGpPWpGaD
Lurasidone—HTR7—Signaling by GPCR—AKT1—atherosclerosis	2.38e-05	0.000112	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—APOE—atherosclerosis	2.38e-05	0.000112	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—LEP—atherosclerosis	2.38e-05	0.000112	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—SERPINE1—atherosclerosis	2.37e-05	0.000112	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—LIPC—atherosclerosis	2.37e-05	0.000112	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PIK3CG—atherosclerosis	2.36e-05	0.000111	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CAV1—atherosclerosis	2.35e-05	0.000111	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—APOC3—atherosclerosis	2.35e-05	0.000111	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—APOA1—atherosclerosis	2.35e-05	0.000111	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—LDLR—atherosclerosis	2.34e-05	0.00011	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—SERPINE1—atherosclerosis	2.3e-05	0.000108	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—MAPK3—atherosclerosis	2.29e-05	0.000108	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CETP—atherosclerosis	2.28e-05	0.000108	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—ESR1—atherosclerosis	2.27e-05	0.000107	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—INS—atherosclerosis	2.27e-05	0.000107	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—NOS3—atherosclerosis	2.26e-05	0.000107	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—MAPK3—atherosclerosis	2.26e-05	0.000107	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—F2—atherosclerosis	2.24e-05	0.000106	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—INS—atherosclerosis	2.23e-05	0.000105	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CCL2—atherosclerosis	2.23e-05	0.000105	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—ALB—atherosclerosis	2.23e-05	0.000105	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—VEGFA—atherosclerosis	2.2e-05	0.000104	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CCL2—atherosclerosis	2.2e-05	0.000104	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—IGF1—atherosclerosis	2.19e-05	0.000104	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—NOS3—atherosclerosis	2.19e-05	0.000103	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—SCARB1—atherosclerosis	2.19e-05	0.000103	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—STAT3—atherosclerosis	2.18e-05	0.000103	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IGF1—atherosclerosis	2.16e-05	0.000102	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CG—atherosclerosis	2.14e-05	0.000101	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—NOS3—atherosclerosis	2.13e-05	0.0001	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—MAPK3—atherosclerosis	2.08e-05	9.83e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—SERPINE1—atherosclerosis	2.08e-05	9.83e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—HMGCR—atherosclerosis	2.06e-05	9.75e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—MAPK3—atherosclerosis	2.05e-05	9.69e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—SERPINE1—atherosclerosis	2.05e-05	9.67e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—INS—atherosclerosis	2.03e-05	9.58e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—TGFB1—atherosclerosis	2.02e-05	9.54e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CXCL8—atherosclerosis	2.01e-05	9.48e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CCL2—atherosclerosis	2e-05	9.42e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—NOS3—atherosclerosis	1.99e-05	9.38e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IGF1—atherosclerosis	1.96e-05	9.27e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—NOS3—atherosclerosis	1.96e-05	9.23e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PTGS2—atherosclerosis	1.95e-05	9.19e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CXCL8—atherosclerosis	1.94e-05	9.17e-05	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—AKT1—atherosclerosis	1.94e-05	9.16e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—IL6—atherosclerosis	1.91e-05	9.02e-05	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—AKT1—atherosclerosis	1.88e-05	8.86e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—SERPINE1—atherosclerosis	1.86e-05	8.8e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—IL6—atherosclerosis	1.85e-05	8.72e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ABCA1—atherosclerosis	1.84e-05	8.69e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MMP9—atherosclerosis	1.82e-05	8.58e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—NFKB1—atherosclerosis	1.8e-05	8.48e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—NOS3—atherosclerosis	1.78e-05	8.4e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MAPK8—atherosclerosis	1.77e-05	8.34e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CXCL8—atherosclerosis	1.76e-05	8.32e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—AKT1—atherosclerosis	1.76e-05	8.32e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MMP9—atherosclerosis	1.76e-05	8.3e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—NFKB1—atherosclerosis	1.74e-05	8.21e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CXCL8—atherosclerosis	1.74e-05	8.19e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MAPK8—atherosclerosis	1.71e-05	8.07e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—AKT1—atherosclerosis	1.71e-05	8.05e-05	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—AKT1—atherosclerosis	1.7e-05	8.04e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—IL6—atherosclerosis	1.68e-05	7.92e-05	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—AKT1—atherosclerosis	1.68e-05	7.91e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—IL6—atherosclerosis	1.65e-05	7.79e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—VEGFA—atherosclerosis	1.63e-05	7.7e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—STAT3—atherosclerosis	1.62e-05	7.62e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MMP9—atherosclerosis	1.6e-05	7.53e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—HMOX1—atherosclerosis	1.58e-05	7.45e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CXCL8—atherosclerosis	1.58e-05	7.45e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—VEGFA—atherosclerosis	1.58e-05	7.45e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—NFKB1—atherosclerosis	1.58e-05	7.45e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MMP9—atherosclerosis	1.57e-05	7.41e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—STAT3—atherosclerosis	1.56e-05	7.38e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—NFKB1—atherosclerosis	1.55e-05	7.33e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MAPK8—atherosclerosis	1.55e-05	7.32e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—AKT1—atherosclerosis	1.55e-05	7.3e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MAPK3—atherosclerosis	1.54e-05	7.28e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MAPK8—atherosclerosis	1.53e-05	7.2e-05	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—AKT1—atherosclerosis	1.53e-05	7.2e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—IL6—atherosclerosis	1.52e-05	7.19e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—AKT1—atherosclerosis	1.52e-05	7.19e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—APOB—atherosclerosis	1.51e-05	7.14e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—IL6—atherosclerosis	1.5e-05	7.09e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—TGFB1—atherosclerosis	1.5e-05	7.07e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MAPK3—atherosclerosis	1.49e-05	7.05e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GSTM1—atherosclerosis	1.47e-05	6.94e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—TGFB1—atherosclerosis	1.45e-05	6.84e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—LPL—atherosclerosis	1.44e-05	6.82e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—VEGFA—atherosclerosis	1.43e-05	6.76e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MMP9—atherosclerosis	1.43e-05	6.74e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—STAT3—atherosclerosis	1.42e-05	6.69e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—NFKB1—atherosclerosis	1.41e-05	6.67e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—VEGFA—atherosclerosis	1.41e-05	6.65e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GPX1—atherosclerosis	1.41e-05	6.65e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—AKT1—atherosclerosis	1.4e-05	6.63e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—STAT3—atherosclerosis	1.4e-05	6.59e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MAPK8—atherosclerosis	1.39e-05	6.55e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—AKT1—atherosclerosis	1.39e-05	6.54e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CD36—atherosclerosis	1.37e-05	6.48e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MAPK3—atherosclerosis	1.36e-05	6.4e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MAPK3—atherosclerosis	1.33e-05	6.29e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—TGFB1—atherosclerosis	1.31e-05	6.21e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—MTHFR—atherosclerosis	1.3e-05	6.14e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—TGFB1—atherosclerosis	1.29e-05	6.11e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—VEGFA—atherosclerosis	1.28e-05	6.05e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PPARA—atherosclerosis	1.28e-05	6.02e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—STAT3—atherosclerosis	1.27e-05	5.99e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—AGT—atherosclerosis	1.24e-05	5.83e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MAPK3—atherosclerosis	1.21e-05	5.73e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—APOE—atherosclerosis	1.21e-05	5.71e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—AKT1—atherosclerosis	1.2e-05	5.69e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CAV1—atherosclerosis	1.2e-05	5.66e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—APOA1—atherosclerosis	1.2e-05	5.65e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—TGFB1—atherosclerosis	1.18e-05	5.55e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—IL6—atherosclerosis	1.13e-05	5.33e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CG—atherosclerosis	1.09e-05	5.16e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—IL6—atherosclerosis	1.09e-05	5.15e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PPARG—atherosclerosis	1.05e-05	4.98e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—AKT1—atherosclerosis	1.04e-05	4.91e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—INS—atherosclerosis	1.03e-05	4.88e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—AKT1—atherosclerosis	1.01e-05	4.75e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—IL6—atherosclerosis	9.91e-06	4.68e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—AKT1—atherosclerosis	9.79e-06	4.62e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IL6—atherosclerosis	9.75e-06	4.6e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ALB—atherosclerosis	9.48e-06	4.47e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—AKT1—atherosclerosis	9.14e-06	4.31e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—NOS3—atherosclerosis	9.07e-06	4.28e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—AKT1—atherosclerosis	8.99e-06	4.24e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IL6—atherosclerosis	8.87e-06	4.19e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PTGS2—atherosclerosis	8.29e-06	3.91e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—AKT1—atherosclerosis	8.18e-06	3.86e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—AKT1—atherosclerosis	4.17e-06	1.97e-05	CbGpPWpGaD
